Advertisement
ALEC vs ZVRA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALEC is a Buy and ZVRA is a StrongBuy.
ALEC in upward trend: price rose above 50-day moving average on November 04, 2026
ALEC moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend. In 30 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on ALEC as a result. In 78 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for ALEC just turned positive on October 27, 2026. Looking at past instances where ALEC's MACD turned positive, the stock continued to rise in 33 of 39 cases over the following month. The odds of a continued upward trend are 85%.
The 10-day moving average for ALEC crossed bullishly above the 50-day moving average on November 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 64%.
Following a +6.91% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALEC advanced for three days, in 218 of 260 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALEC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
ALEC broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ALEC entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-25.646) is normal, around the industry mean (3.498). P/E Ratio (-2.101) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (15.060) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. ALEC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALEC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
ZVRA's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for ZVRA turned positive on October 29, 2026. Looking at past instances where ZVRA's MACD turned positive, the stock continued to rise in 42 of 49 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ZVRA as a result. In 78 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
ZVRA moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +15.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where ZVRA advanced for three days, in 232 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ZVRA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.
ZVRA broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ZVRA entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 29 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. ZVRA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 76 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ZVRA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.162) is normal, around the industry mean (3.498). P/E Ratio (12.073) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (10.667) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.176) is also within normal values, averaging (440.869).
ALEC | ZVRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 42 | 24 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 92 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 76 | |
SMR RATING 1..100 | 100 | 29 | |
PRICE GROWTH RATING 1..100 | 37 | 45 | |
P/E GROWTH RATING 1..100 | 93 | 86 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ALEC's Valuation (6) in the Biotechnology industry is significantly better than the same rating for ZVRA (92) in the null industry. This means that ALEC’s stock grew significantly faster than ZVRA’s over the last 12 months.
ZVRA's Profit vs Risk Rating (76) in the null industry is in the same range as ALEC (100) in the Biotechnology industry. This means that ZVRA’s stock grew similarly to ALEC’s over the last 12 months.
ZVRA's SMR Rating (29) in the null industry is significantly better than the same rating for ALEC (100) in the Biotechnology industry. This means that ZVRA’s stock grew significantly faster than ALEC’s over the last 12 months.
ALEC's Price Growth Rating (37) in the Biotechnology industry is in the same range as ZVRA (45) in the null industry. This means that ALEC’s stock grew similarly to ZVRA’s over the last 12 months.
ZVRA's P/E Growth Rating (86) in the null industry is in the same range as ALEC (93) in the Biotechnology industry. This means that ZVRA’s stock grew similarly to ALEC’s over the last 12 months.
| ALEC | ZVRA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 85% | N/A |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 81% |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 86% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 80% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 80% |
| Advances ODDS (%) | 2 days ago 84% | 4 days ago 82% |
| Declines ODDS (%) | 10 days ago 87% | 2 days ago 75% |
| BollingerBands ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 84% | 2 days ago 82% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ALEC’s FA Score shows that 1 FA rating(s) are green while ZVRA’s FA Score has 1 green FA rating(s).
- ALEC’s FA Score: 1 green, 4 red.
- ZVRA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ALEC’s TA Score shows that 5 TA indicator(s) are bullish while ZVRA’s TA Score has 4 bullish TA indicator(s).
- ALEC’s TA Score: 5 bullish, 5 bearish.
- ZVRA’s TA Score: 4 bullish, 4 bearish.
Price Growth
ALEC (@Biotechnology) experienced а +15.35% price change this week, while ZVRA (@Biotechnology) price change was +6.09% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -0.49%. For the same industry, the average monthly price growth was -6.84%, and the average quarterly price growth was -13.86%.
Reported Earning Dates
ALEC is expected to report earnings on Mar 02, 2027.
ZVRA is expected to report earnings on Mar 10, 2027.
Industries' Descriptions
@Biotechnology (-0.49% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
ALEC and
Correlation & Price change
A.I.dvisor indicates that over the last year, ALEC has been loosely correlated with EDIT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if ALEC jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To ALEC | 1D Price Change % | ||
|---|---|---|---|---|
| ALEC | 100% | +3.95% | ||
| EDIT - ALEC | 49% Loosely correlated | -4.99% | ||
| BCYC - ALEC | 47% Loosely correlated | N/A | ||
| VYGR - ALEC | 43% Loosely correlated | -3.56% | ||
| ARVN - ALEC | 43% Loosely correlated | -0.14% | ||
| SANA - ALEC | 42% Loosely correlated | -5.76% | ||
More | ||||
ZVRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with EDIT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To ZVRA | 1D Price Change % | ||
|---|---|---|---|---|
| ZVRA | 100% | -0.59% | ||
| EDIT - ZVRA | 48% Loosely correlated | -4.99% | ||
| VYGR - ZVRA | 46% Loosely correlated | -3.56% | ||
| KYTX - ZVRA | 40% Loosely correlated | +0.79% | ||
| MGTX - ZVRA | 40% Loosely correlated | +0.62% | ||
| ALEC - ZVRA | 39% Loosely correlated | +3.95% | ||
More | ||||